Cardiovascular Events in Patients With Hypertension and Left Ventricular Hypertrophy: A LIFE Study

M. Kamalesh,Tamara S. Evans,Markku S. Nieminen,Amy S. Friend,H. Ibsen,Stevo Julius,M. Olsen,E. Schellhase,E. Sverre,K. Wachtell,Lars H Lindholm,R. Devereux

Abstract:Background: Patients with left ventricular hypertrophy (LVH) have been shown to have increased incidence of sudden cardiac death (SCD). This analysis assessed predictors of SCD in a large cohort of hypertensive patients with ECG LVH. Methods: In the LIFE (n=9,193), a double-blind, randomized, parallel-group trial, 190 patients died suddenly within 24 hours of onset of symptoms during the average 4.8 year follow-up period. Results: Patients with SCD were older, more often male and had higher ECG LVH, albuminuria and more frequent history of atrial fibrillation, diabetes, coronary heart and cerebral vascular disease. SCD was not predicted by systolic or diastolic blood pressure, body mass index, cholesterol, potassium or history of peripheral vascular disease. In multivariate Cox analysis Cornell voltage-duration product predicted SCD (Table) and remained predictive in a subgroup (n=3,617) without history of coronary heart disease or albuminuria. The 1-year Cornell voltage-duration product was more predictive than baseline indicating that regression of LVH is more predictive than baseline LVH. Treatment with losartan compared to atenolol was not associated with a lower SCD rate (HR=0.88 [95% CI: 0.66-1.17], p=0.364). Conclusion: Baseline LVH predicts SCD independent of history of coronary heart disease and other cardiovascular risk factors and remains predictive in the subpopulation without signs of atherosclerosis. Furthermore, losartan vs. atenolol treatment appears to benefit SCD equally.

Medicine